Ritter Pharmaceuticals Inc (RTTR) Stock Rating Reaffirmed by Maxim Group
Ritter Pharmaceuticals Inc (NASDAQ:RTTR)‘s stock had its “buy” rating reissued by research analysts at Maxim Group in a research note issued to investors on Monday.
Separately, Zacks Investment Research downgraded Ritter Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, July 13th.
Ritter Pharmaceuticals (NASDAQ:RTTR) opened at 2.30 on Monday. The firm’s market cap is $19.74 million. Ritter Pharmaceuticals has a 52 week low of $0.98 and a 52 week high of $2.63. The firm’s 50 day moving average price is $1.60 and its 200-day moving average price is $1.55.
Ritter Pharmaceuticals (NASDAQ:RTTR) last announced its quarterly earnings data on Monday, August 8th. The company reported ($0.48) EPS for the quarter, missing analysts’ consensus estimates of ($0.34) by $0.14. On average, analysts forecast that Ritter Pharmaceuticals will post ($1.38) EPS for the current year.
About Ritter Pharmaceuticals
Ritter Pharmaceuticals, Inc develops therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The Company’s segment is focusing on the development and commercialization of RP-G28. The Company conducts human gut health research by exploring metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics into applications intended to have impact on a patient’s health.
Receive News & Stock Ratings for Ritter Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ritter Pharmaceuticals Inc and related stocks with our FREE daily email newsletter.